News

Axsome Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved AXS-07 (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. This novel oral medication combines meloxicam, a nonsteroidal anti-inflammatory drug, and rizatriptan, a serotonin receptor agonist, to provide rapid and sustained relief from migraine pain.

Are you a neurology resident, pediatric neurology resident, or a headache medicine fellow with a passion for headache research, medical education, and writing? Headache: The Journal of Head and Face Pain is looking for dedicated trainees to join its Editorial Board as part of the Resident & Fellows Assistant Editor Team!

The American Headache Society is excited to announce scholarship opportunities now available to attend the 67th Annual Scientific Meeting, the premiere venue for cutting-edge advances in Headache Medicine, taking place June 19-22, 2025 at the Minneapolis Convention Center in Minneapolis, MN.

On behalf of the Scientific Program Committee, AHS is excited to announce we are now accepting the submission of abstracts of original contributions on any topic related to headache for presentation at the 67th Annual Scientific Meeting, being held June 19-22, 2025 at the Minneapolis Convention Center in Minneapolis, MN.

In a groundbreaking initiative, a multi-stakeholder international group of experts led by the American Headache Society in close collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) and the International Headache Society (IHS), has identified critical research priorities for the headache field. 

“Dr. Tavasoli is an excellent fellow. He is kind, compassionate, and caring towards his patients. He is dedicated to patient care and research in Headache Medicine. He excels in academics, and recently presented at the International Headache Academy on a case of an 11 month old with infantile colic/migraine variant.”

“We are nominating Dr. Guy Greco who is one of our two outstanding fellows this year. What stands out in his work is his sincere care and patience for our patients. He always takes his time to be thoughtful and considerate, even during a busy clinic day...

The American Headache Society (AHS), dedicated to improving the lives of those affected by migraine and other headache disorders, is pleased to announce a call for proposals as part of a Quality Improvement (QI) initiative in headache medicine.

“Dr. Pareek is an upbeat, knowledgeable, caring, and very skilled pediatric headache fellow. It his been a joy to work with her over the last few months. Not only does she excel clinically, but she also remains involved in publications, chart reviews, and QI projects...

“Zachary was nominated by residents as best fellow educator and by patients as top caring physician. From the first day of his fellowship, he proved to be passionate about headache medicine...

AHS recognizes that to fulfill its core goal of improving the lives of people impacted by migraine and other headache disorders, healthcare advocacy is essential.

"Dr. Yousaf is an excellent clinical fellow, adult trained, but doing a pediatric fellowship to increase his knowledge of pediatric headache management. By his initiative, he started a pictorial series of the pediatric migraine experience...

Computerization of medicine can be a boon or a burden. The Clinical Informatics Special Interest Section brings together AHS members who want to help our specialty navigate these rapid changes in our practice.

Adult neurology residents, pediatric neurology residents, postdoctoral researchers, and headache medicine fellows are eligible to apply for a 2-year term, beginning July 1, 2024 and ending June 30, 2026.